Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Investigational gene therapy for choroideremia does not meet study endpoints ➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD ➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant ➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies ➤ ASCRS events
➤ Results from Phase 1 clinical trial of intranasal glaucoma drug ➤ Phase 3 clinical trial of new ophthalmic corticosteroid nanoemulsion ➤ Pharmaceutical company expands gene therapy pipeline ➤ Companies enter agreement to develop next-generation decision support software ➤ Study: Association between caffeine intake and glaucoma
➤ Early termination of study evaluating Beovu ➤ NDA resubmitted to FDA for investigational macular edema treatment ➤ First peer-reviewed paper on visual recovery in a blind patient treated with optogenetic therapy ➤ Study: New riboflavin formulation enhances transepithelial crosslinking ➤ Enrollment complete for blepharitis trial ➤ Companies partner to develop human-induced pluripotent stem cell-derived therapies for ocular diseases ➤ ASCRS events
➤ Positive topline results in Phase 3 study for temporary presbyopia therapy ➤ Study: New therapy for ocular infections ➤ Analysis of more than half a million cataract surgeries yields PCO insights ➤ Patients blinded from AMD benefit from visual prosthetic ➤ New company focuses on refractive pharmaceutical treatments ➤ ASCRS events
➤ FDA approves spheric, monofocal IOL ➤ Phase 2/3 study of gene therapy for retinitis pigmentosa does not meet primary endpoint ➤ Study: Compounded cyclosporine drop significantly improves OSDI scores ➤ Subretinal injector receives FDA pre-market approval ➤ Three companies form strategic alliance to develop cell therapies ➤ ASCRS events
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13
➤ Positive topline results for Phase 3 trial of drug for allergic conjunctivitis ➤ Phase 2 trial of progesterone topical gel for DED begins ➤ Breakthrough Device Designation granted to remote glaucoma management system ➤ Glaukos enters into licensing agreement for presbyopia treatment ➤ Increase in laser vision correction procedures continues ➤ Guide on climate change and eye health ➤ ASCRS events
➤ FDA approves next-generation phaco machine ➤ Study: Endogenous compound reduces glaucomatous vision loss independent of IOP ➤ Successful transplant of stem cell-derived retinal ganglion cells in lab ➤ Phase 2 clinical trial for intravitreal dexamethasone implant ➤ ASCRS events
➤ Topline data from a Phase 3 study investigating first-in-class DED drop ➤ Research initiative focuses on new glaucoma treatments ➤ Phase 2 trial for oral treatment of diabetic retinopathy begins ➤ New SLT trial recruiting study sites ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.